Functionalized microcarriers for Enhanced CAR T cell manufacturing
January 27-31, 2019
Adoptive cell therapy using chimeric antigen receptor (CAR) T cells has shown immense promise in treating cancer. In 2017, Novartis and Kite Pharma both acquired FDA approval for their CAR T cell therapies targeted toward B cell malignancies. Despite these successes, manufacturing high-quality T cells at scale has proven challenging. Notably, current processes rely on bead-based expansion and suspension-cell bioreactors, which do not recapitulate the high cell density and robust signaling found in the lymph nodes.
Please click Additional Files below to see the full abstract.
Nate Dwarshuis, Hannah Wilson Song, Krishnendu Roy, and Anokhi Patel, "Functionalized microcarriers for Enhanced CAR T cell manufacturing" in "Advancing Manufacture of Cell and Gene Therapies VI", Dolores Baksh, GE Healthcare, USA Rod Rietze, Novartis, USA Ivan Wall, Aston University, United Kingdom Eds, ECI Symposium Series, (2019). https://dc.engconfintl.org/cell_gene_therapies_vi/97